-Philippe Guillaume Researcher Activity Profile

Research Author Detailed Information 

Philippe Guillaume Publication Rate By Year

Philippe Guillaume has published 7 paper(s) in 2007, 2 paper(s) in 2008, for a total of 9 research publications in total.

Philippe P Guillaume Author Information

LAST NAME: guillaume

FIRST NAME: philippe

INITIALS: P

AFFILIATION:

Papers

Philippe Guillaume's Publication Record

1. The use of the dog electroencephalogram (EEG) in safety pharmacology to evaluate proconvulsant risk. Year Published: 2007
Porsolt and Partners Pharmacology, 9bis rue Henri Martin, 92100 Boulogne-Billancourt, France. ndurmuller@porsolt.com
2. Low TCR avidity and lack of tumor cell recognition in CD8(+) T cells primed with the CEA-analogue CAP1-6D peptide. Year Published: 2007
Unit of Immunotherapy of Human Tumors, IRCCS Istituto Nazionale Tumori, Via Venezian 1, 20133, Milan, Italy.
3. A constant affinity threshold for T cell tolerance. Year Published: 2007
Laboratory of Transplantation Immunology, Department of Research, University Hospital, 4031 Basel, Switzerland.
4. A constant affinity threshold for T cell tolerance. Year Published: 2007
Laboratory of Transplantation Immunology, Department of Research, University Hospital, 4031 Basel, Switzerland.
5. Molecular Design of the C{alpha} Interface Favors Specific Pairing of Introduced TCR{alpha} in Human T Cells. Year Published: 2007
Medical Clinic (III) and Polyclinic, Department of Hematology and Oncology, Johannes Gutenberg-University, Mainz, Germany;
6. Molecular design of the Calpha interface favors specific pairing of introduced TCRalpha in human T cells. Year Published: 2007
Medical Clinic (III) and Polyclinic, Department of Hematology and Oncology, Johannes Gutenberg-University, Mainz, Germany. hvoss@uni-mainz.de
7. RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses. Year Published: 2008
8. RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses. Year Published: 2008
Department of Internal Medicine III, University of Ulm, Ulm, Germany. michael.schmitt@uniklinik-ulm.de
9. Molecular design of the Calphabeta interface favors specific pairing of introduced TCRalphabeta in human T cells. Year Published: 2007
Medical Clinic (III) and Polyclinic, Department of Hematology and Oncology, Johannes Gutenberg-University, Mainz, Germany. hvoss@uni-mainz.de